# Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

> **NCT03290508** · — · TERMINATED · sponsor: **Myriad Genetic Laboratories, Inc.** · enrollment: 524 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Prolaris Testing

## Key facts

- **NCT ID:** NCT03290508
- **Lead sponsor:** Myriad Genetic Laboratories, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-14
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-01-14
- **Target enrollment:** 524 (ACTUAL)
- **Why stopped:** There is sufficient follow-up data to meet the endpoints of the study.
- **Last updated:** 2022-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03290508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03290508, "Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03290508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*